Hsp90 inhibitors: A potential treatment for latent EBV infection?

Cell Cycle

Volumn 9, Issue 9, 2010, Pages 1665-1666

  Sun, Xiaoping ^a   Kenney, Shannon C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; EPSTEIN BARR VIRUS ANTIGEN 1; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; TANESPIMYCIN;

EDITORIAL; EPSTEIN BARR VIRUS INFECTION; NONHUMAN;

HUMAN HERPESVIRUS 4;

EID: 77953605309     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.9.11594     Document Type: Editorial

References (12)

1. Kieff E, et al. Fields' Virology 2007; 5:2603-54.
2. Lindner SE, et al. Plasmid 2007; 58:1-12.
3. Sun X, et al. Proc Natl Acad Sci USA 2010; 107:3146-51.
4. Prodromou C, et al. Cell 1997; 90:65-75.
5. Taldone T, et al. Curr Opin Pharmacol 2008; 4:370-4.
6. Geller R, et al. Genes Dev 2007; 21:195-205.
7. Kamal A, et al. Nature 2003; 425:407-10.
8. Levitskaya J, et al. Proc Natl Acad Sci USA 1997; 94:12616-21.
9. Yin Y, et al. Science 2003; 301:1371-4.
10. Kim TS, et al. Mol Biol Cell 2006; 17:824-33.
11. Tellam J, et al. Proc Natl Acad Sci USA 2008; 105:9319-24.
12. Taldone T, et al. Curr Top Med Chem 2009; 9:1436-46.